(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) fell by a staggering 33.33% in 21 sessions from €0.12 to €0.08 at 14:09 EST on Friday, after four consecutive sessions in a row of losses. BEL 20 is rising 0.92% to €3,531.73, after two sequential sessions in a row of gains.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.02.
Volume
Today’s last reported volume for BIOSENIC is 120752 which is 75.14% below its average volume of 209519.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC’s stock is considered to be overbought (>=80).
Volatility
BIOSENIC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.63%, a negative 2.45%, and a positive 4.18%.
BIOSENIC’s highest amplitude of average volatility was 4.63% (last week), 4.80% (last month), and 4.18% (last quarter).
More news about BIOSENIC (BIOS.BR).
